Introduction

Generic drugs provide same therapeutic effect as an originator, at more affordable price. Still, they are not best adopted. We conducted a survey to understand oncologist’s perceptions and attitudes towards generic drugs and understand factors that influence their prescribing behavior.

Methods

Oncologists from 15 countries were invited for this cross–sectional survey. Assessment was completed using a series of structured, closed qualitative questions to which participants could select from predefined answers.

Results

Fifty three oncologists participated in the. About 70% oncologists acknowledged high–cost of originator drugs often limits providing guidelines based therapy to patients. Most of the participants (86%) opined that quality of generic drugs depends on the manufacturing company. More than 90% respondents agreed that good generic companies often match the quality of originator drugs. A majority (67.5%) of the oncologists believed that side effects caused by generics were similar to those caused by originator drugs.

Conclusions

Our finding suggest that educational programs highlighting the benefits of generic drugs should be imparted to the key stakeholder including patients.